| Literature DB >> 28249575 |
Michael Pritsch1,2, Ahmed Zeynudin3,4,5, Maxim Messerer5, Simon Baumer6, Gabriele Liegl5, Soeren Schubert5, Thomas Löscher7, Michael Hoelscher7,8,4, Tefara Belachew3, Andrea Rachow7,8, Andreas Wieser7,8,3,5.
Abstract
BACKGROUND: Multidrug-resistant Gram-negative bacterial infections are recognized as one of the major threats to global health. In this study, we describe for the first time bla NDM-1 gene carrying organisms from Ethiopia consisting of three Acinetobacter baumannii isolates from patients in Jimma.Entities:
Keywords: Acinetobacter baumannii; Carbapenemase; East-Africa; Ethiopia; NDM-1; New Delhi metallo-beta-lactamase
Mesh:
Substances:
Year: 2017 PMID: 28249575 PMCID: PMC5333390 DOI: 10.1186/s12879-017-2289-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Basic demographic and medical data of patients A–C
| Patient | A | B | C |
|---|---|---|---|
| Patient type | Inpatient | Inpatient | Inpatient |
| Department | ICU, surgical department | surgical department | ICU |
| Underlying disease | Hypertension | None | Asthma bronchiale |
| Clinical diagnosis | Hemopneumothorax | Inguinal abscess | Generalized peritonitis secondary to PUD and bronchial asthma, laparotomy |
| Specimen type | Fluid from hemopneumothorax | Abscess fluid/drain | Peritoneal swab |
| Antibiotics used during hospital stay |
| ceftazidime, cloxacillin, | ceftriaxone, metronidazol, cloxacillin |
| Travel history | None | None | None |
| Outcome | Improved | Improved | Died |
Treatment with substance tested susceptible depicted in bold
Antimicrobial susceptibility testing results for the Acinetobacter baumannii
| Antimicrobial compound | MIC breakpoint (μg/ml) | Isolate A | Isolate B | Isolate C | ||||
|---|---|---|---|---|---|---|---|---|
| μg/ml | mm | μg/ml | mm | μg/ml | mm | |||
| S ≤ | R > |
|
|
| ||||
| Chloramphenicol | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Fosfomycin | – | – | >256 | – | >256 | – | >256 | – |
| Ciprofloxacin | 1 | 1 | >32 | n.a. | >32 | n.a. | >32 | n.a. |
| Erythromycin | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Amoxicillin | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Amoxicillin/Clavulanic Acid | – | – | >256 | 12 | >256 | 13 | >256 | 14 |
| Cefoxitin | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Ceftazidime | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Cefepime | – | – | >256 | n.a. | >256 | n.a. | >256 | n.a. |
| Meropenem | 2 | 8 | >32 | n.a. | >32 | 8 | >32 | n.a. |
| Aztreonam | – | – | >256 | – | >256 | – | >256 | – |
| Amikacin | 8 | 16 |
|
|
|
|
|
|
| Gentamicin | 4 | 4 | 32 | n.a. | 32 | n.a. | 32 | n.a. |
| Trimethoprim/Sulfamethoxazole | 2 | 4 |
|
| 32 | n.a. | 32 | n.a. |
| Polymyxin B | 2 | 2 |
|
|
|
|
|
|
| Tetracycline | – | – | 12 | 18 | 12 | 20 | 12 | 21 |
strains Breakpoints and testing according to EUCAST v 4.0 [19]. Treatment options printed in bold. Disc diffusion diameters in mm in second column; n.a.: no inhibition around disc 6 mm); −:not performed; Disc diffusion diameter cutoff values shown in brackets in respective relevant fields, if no cutoff values are shown EUCAST v 4.0 does not indicate a cutoff value
Fig. 1MLST-based phylogenetic tree using the Oxford-scheme. The Sequence Types, countries and years of isolation are indicated when known. Green asterisks indicate the proven presence of an NDM-1-plasmid (Isolate A, Isolate B, Isolate C, 6200, B11911, A1, ZW85-1). The scale-bar represents the number of SNPs per nucleotide
Fig. 2Gene-map of the NDM-1 cassette as sequenced in the three isolates from Ethiopia. The sequence was found to be identical to published sequences of NDM-1 in other organisms isolated from multiple places on different continents. There are clearly identifiable transposase genes as well as other antibiotic resistance genes in close proximity of NDM-1; PRAI: phosphoribosylanthranilate isomerase; TAT: twin-arginine translocation pathway